Roger Revelle

Reveleer Launches Risk Adjustment 2.0: New AI-Driven Coding Capabilities for Health Plans and Risk-Bearing Providers

Retrieved on: 
Tuesday, August 30, 2022
PHI, AI, CEO, Roger Hawkins (drummer), HCC, Risk, Confidence, Artificiality, Pressure, Collection, Hotel manager, Intelligence, Machine learning, Natural language processing, OCR, RISE, Modern Healthcare, NLP, Automation, Acquisition, Review, Health, Medical device, Roger Revelle

GLENDALE, Calif., Aug. 30, 2022 /PRNewswire/ -- Today Reveleer, a healthcare technology company using intelligent automation to empower data driven healthcare for payers in all lines of business, announced the launch of Reveleer for Risk 2.0. (Risk 2.0), the revolutionary and only end-to-end cloud-based platform for clinical data acquisition and coding for health plans nationwide. Proprietary Artificial Intelligence-driven capabilities allow health plans to confidently plan and execute risk adjustment programs with critical support to automate the collection, analysis, review, and submission of risk adjustment data. To receive a live demonstration of Risk 2.0, visit the Reveleer booth #309 @ RISE West 2022 Summit in Los Angeles, August 31 thru September 2, 2022.

Key Points: 
  • (Risk 2.0), the revolutionary and only end-to-end cloud-based platform for clinical data acquisition and coding for health plans nationwide.Proprietary Artificial Intelligence-driven capabilities allow health plans to confidently plan and execute risk adjustment programs with critical support to automate the collection, analysis, review, and submission of risk adjustment data.
  • As health plans and providers face increasing pressure to do more with less, Risk 2.0 provides a path to transformation.
  • Customizable AI-driven coding guidelines enable health plans to incorporate their own plan-specific rule sets within the platform.
  • Leveraging proprietary technology, robust data sets, and subject matter expertise, Reveleer provides complete record retrieval and review services so health plans can confidently plan and execute risk adjustment programs that deliver more value and improved outcomes.

bioAffinity Technologies Announces Xavier T. Reveles Promoted to Vice President of Operations

Retrieved on: 
Thursday, October 14, 2021
Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Lung, Patient, HIV disease progression rates, Technology, Diabetes, Diagnosis, COVID-19, Cancer, Publication, Pathology, UT Health San Antonio Cancer Center, LDT, Physician, Prostate, Flow cytometry, Laboratory, Breast, Therapy, American Society for Clinical Pathology, Multimedia, Disease, Cytogenetics, Invitae, Schizophrenia, CLIA, Roger Revelle, Society, CG, University, Research, Company, Oncogene, 2021 Essex County Council election, University of Texas Health Science Center at San Antonio, Lung cancer, CAP, Acquisition, Medical imaging

bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations.

Key Points: 
  • bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations.
  • Reveles will be responsible for overseeing the commercialization of the Companys diagnostic products, including CyPath Lung, a highly accurate, non-invasive test to diagnose early-stage lung cancer.
  • Prior to joining bioAffinity, Mr. Reveles was Laboratory Director for Oncopath Laboratory START Cancer Center in San Antonio, Texas.
  • bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.

“We Must Eliminate The Noise,” Reflected Cerner’s New President And CEO

Retrieved on: 
Tuesday, October 12, 2021
Population health, Twitter, Health, AI, Method, Data, Caregiver, Conference, Information, COVID-19, Nursing, Merck, Roger Revelle, LinkedIn, Failure, Time, GLOBE, Industry, Gerberding, Noise, Instagram, Lung cancer, U.S. Securities and Exchange Commission, Disclosure, EHR, Security (finance), Knowledge, CEO, CERN, Documentation, Leadership, Solution, Compliance, Patient, Government, Pit additive, Technology, Organization, Pharmaceutical industry

KANSAS CITY, Mo., Oct. 12, 2021 (GLOBE NEWSWIRE) -- During the opening keynote at Cerner Health Conference , Cerners new President and CEO, David Feinberg, M.D.

Key Points: 
  • KANSAS CITY, Mo., Oct. 12, 2021 (GLOBE NEWSWIRE) -- During the opening keynote at Cerner Health Conference , Cerners new President and CEO, David Feinberg, M.D.
  • Julie Louise Gerberding, M.D., M.P.H., chief patient officer and executive vice president, population health and sustainability at Merck, and member of Cerners board of directors, kicked off the conference introducing Feinberg.
  • During his keynote, Feinberg noted Gartner recently acknowledged Cerners work to tackle clinician burnout by highlighting a key tool in this effort, Essential Clinical Datasets.
  • The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made.

Media Invited to Preview Expedition to Ocean Twilight Zone

Retrieved on: 
Friday, June 22, 2018
Oceanography, Physical geography, Earth, Biological oceanography, Chemical oceanography, Geochemistry, Roger Revelle, Photosynthesis, Sea, Carbon cycle, Plankton, Underwater glider

WASHINGTON, June 22, 2018 /PRNewswire-USNewswire/ --Media are invited to Seattle on Friday, Aug. 9, to preview a seaborne expedition to study microscopic organisms in the dark depths of the sea that play a critical role in removing carbon dioxide from Earth's atmosphere.

Key Points: 
  • WASHINGTON, June 22, 2018 /PRNewswire-USNewswire/ --Media are invited to Seattle on Friday, Aug. 9, to preview a seaborne expedition to study microscopic organisms in the dark depths of the sea that play a critical role in removing carbon dioxide from Earth's atmosphere.
  • Led by NASA and the National Science Foundation, the Export Processes in the Ocean from Remote Sensing ( EXPORTS ) expedition is the first effort of its kind to study microscopic plankton and their impact on Earth's carbon cycle important information for climate modeling.
  • Media will hear from EXPORTS scientists and tour the University of Washington Applied Physics Laboratory, home of the Seaglider autonomous underwater vehicle that will be used in the expedition.
  • Research Vessels Roger Revelle and Sally Ride , operated by Scripps Institution of Oceanography at the University of California San Diego, also will be open to media for tours.